Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

The firm saw an improvement in progression-free survival for patients on the ivonescimab regimen and a trend toward improved overall survival.

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...